The National Institute for Health Research (NIHR) awarded a grant worth more than £1.5 million (about $2.1 million) to support a U.K. clinical trial investigating ways of safely lowering the treatment burden of cystic fibrosis (CF), a top priority for patients and their healthcare teams. The randomized and open-label trial, called CF STORM, will enroll 764 CF patients across the U.K. on a stable treatment regimen with Kaftrio (by Vertex; sold as Trikafta in the U.S.),…

You must be logged in to read/download the full post.